(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use...
Stats | |
---|---|
आज की मात्रा | 4.48M |
औसत मात्रा | 599 679 |
बाजार मूल्य | 127.83M |
EPS | $0 ( 2024-03-14 ) |
अगली कमाई की तारीख | ( $0 ) 2024-05-07 |
Last Dividend | $0.667 ( 2014-10-31 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.01 |
ATR14 | $0.0250 (1.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-21 | Baylor-henry Minnie | Sell | 32 800 | Common Stock |
2023-09-21 | Baylor-henry Minnie | Sell | 26 400 | Common Stock |
2023-09-21 | Baylor-henry Minnie | Sell | 12 800 | Stock option (right to buy) |
2023-09-21 | Hoffmann Rolf K | Sell | 64 000 | Common Stock |
2023-09-21 | Hoffmann Rolf K | Sell | 20 000 | Common Stock |
INSIDER POWER |
---|
-64.25 |
Last 96 transactions |
Buy: 1 606 755 | Sell: 5 363 965 |
मात्रा सहसंबंध
Paratek Pharmaceuticals सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध | |
---|---|
PAIC | 0.948 |
SVOK | 0.947 |
BIOL | 0.912 |
RMRM | 0.909 |
YMAB | 0.899 |
SVAC | 0.89 |
AVCT | 0.883 |
TSP | 0.879 |
UK | 0.876 |
GAINL | 0.876 |
10 सबसे अधिक नकारात्मक सहसंबंध | |
---|---|
BOCH | -0.954 |
NETE | -0.938 |
MMAC | -0.912 |
RAVN | -0.903 |
SHSP | -0.9 |
LMRK | -0.894 |
QADA | -0.878 |
VLYPO | -0.862 |
AMRB | -0.862 |
PODD | -0.858 |
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Paratek Pharmaceuticals सहसंबंध - मुद्रा/वस्त्र
Paratek Pharmaceuticals वित्तीय
Annual | 2022 |
राजस्व: | $150.79M |
सकल लाभ: | $127.73M (84.71 %) |
EPS: | $-1.170 |
FY | 2022 |
राजस्व: | $150.79M |
सकल लाभ: | $127.73M (84.71 %) |
EPS: | $-1.170 |
FY | 2021 |
राजस्व: | $130.16M |
सकल लाभ: | $108.63M (83.46 %) |
EPS: | $-1.201 |
FY | 2020 |
राजस्व: | $46.92M |
सकल लाभ: | $38.27M (81.56 %) |
EPS: | $-2.19 |
Financial Reports:
No articles found.
Paratek Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $15.96 | 2014-05-21 |
Last Dividend | $0.667 | 2014-10-31 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | $40.59 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.91 | -- |
Div. Sustainability Score | 0.312 | |
Div.Growth Potential Score | 0.170 | |
Div. Directional Score | 0.241 | -- |
Year | Amount | Yield |
---|---|---|
2014 | $40.59 | 172.60% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.299 | 1.500 | -5.98 | -8.98 | [0 - 0.5] |
returnOnAssetsTTM | -0.287 | 1.200 | -9.57 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.224 | 1.500 | 8.63 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.519 | 0.800 | -2.40 | -1.923 | [1 - 3] |
quickRatioTTM | 0.420 | 0.800 | -2.23 | -1.786 | [0.8 - 2.5] |
cashRatioTTM | 0.211 | 1.500 | 9.94 | 10.00 | [0.2 - 2] |
debtRatioTTM | 1.782 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -1.959 | 1.000 | -1.837 | -1.837 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.189 | 2.00 | -0.0628 | -0.126 | [0 - 30] |
freeCashFlowPerShareTTM | -0.190 | 2.00 | -0.0949 | -0.190 | [0 - 20] |
debtEquityRatioTTM | -1.290 | -1.500 | -5.16 | 7.74 | [0 - 2.5] |
grossProfitMarginTTM | 0.850 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.201 | 1.000 | -6.01 | -6.01 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.0416 | 1.000 | -1.342 | -1.342 | [0.2 - 2] |
assetTurnoverTTM | 0.960 | 0.800 | 6.94 | 5.55 | [0.5 - 2] |
Total Score | 0.312 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.05 | 1.000 | -0.409 | 0 | [1 - 100] |
returnOnEquityTTM | 0.224 | 2.50 | 9.12 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.190 | 2.00 | -0.0632 | -0.190 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.189 | 2.00 | -0.0628 | -0.126 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.179 | 1.500 | -2.14 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0772 | 1.000 | -4.43 | 0 | [0.1 - 0.5] |
Total Score | 0.170 |
Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं